Active soluble post-translationally modified neuregulin isoforms

摘要

The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition- related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.